
An increased risk of deaths for patients in clinical trials receiving this cancer drug and two other drugs led FDA to stop the clinical trials.

An increased risk of deaths for patients in clinical trials receiving this cancer drug and two other drugs led FDA to stop the clinical trials.

Technology is enabling healthcare consumers the freedom to choose. With increasing choices, convenience is at the forefront of the next evolution of healthcare, and companies need to focus on delivering great end-to-end experiences to meet the needs of today’s consumers.

What technology will have the biggest impact on your managed care organization? Healthcare executives weigh in.

Millennials are tomorrow’s leaders, and they bring a lot to the table. Here are some benefits they bring to managed care organizations.

Clinical experience and business acumen are important factors in a successful healthcare leader, but the ability to accept change and help an organization adapt are perhaps the most critical.

This new hospital model offers an opportunity to attract new patients in an efficient, cost-effective setting.

CMS’ Quality Payment Program launched in 2016 as part of MACRA. Here’s what’s in store for Year 2.

PBMs partnering with pharmacies and drug makers may have a solution to nonadherence due to high pharma costs.

The first therapy based on gene transfer has been approved by the FDA. What’s next for healthcare executives?

Hospitals innovatively improve the patient experience as the industry shifts to value-based care.

There are several possible reasons that breastfeeding may influence breast cancer risk, according to the American Institute of Cancer Research. Find out what they are.

New research shows that these certain patients with breast cancer can benefit from genetic testing for all breast cancer genes.

As more specialty drugs are approved, cost control strategies are key.

In an intense healthcare era, there’s no “one-size-fits-all" approach to managing, but here are four things a fearless leader must do.

Political uncertainty plagues new payment arrangement, but private payers embrace new model.

Two Willis Towers Watson surveys have interesting findings about employee healthcare benefits.

Experts share how the declaration could affect how the opioid epidemic is managed.

A top-selling diabetes drug has gained a cardiovascular indication from FDA.

New biosimilars may harm the sales of this autoimmune blockbuster.

Here’s what industry experts think after Cigna’s business model shift.

A new University of California, San Diego-led review has interesting findings about diabetes costs, patient care models and medication therapy.

A new UC Berkeley study has surprising findings about reference pricing and patient drug selection.

Cigna publication project takes a page out of the big pharma and medical technology playbook.

Allegheny Health Network’s Susan Manzi, MD, MPH, discusses the healthcare needs of patients with lupus and other autoimmune disorders.

Administrative costs are a huge burden in healthcare, but there are several process changes that can result in huge savings.

The concepts that power cognitive computing and AI have grown to include substantial healthcare advancements.

Today there are nearly 67,000 genetic tests. With so many tests available, it can be difficult for MCOs to determine what to cover.

FDA approved a targeted new drug to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

An FDA committee will review prescription opioid products containing hydrocodone or codeine to treat coughs in children.

As President Trump declares the opioid epidemic “a national emergency,” a new opioid management program from Express Scripts will limit the number and strength of opioid drugs to first-time patients.